Exploiting FOXM1-orchestrated molecular network for early squamous cell carcinoma diagnosis and prognosis

International Journal of Cancer

Volumn 132, Issue 9, 2013, Pages 2095-2106

  Teh, Muy Teck ^a   Hutchison, Iain L ^b   Costea, Daniela Elena ^c   Neppelberg, Evelyn ^c   Liavaag, Per Gunnar ^d   Purdie, Karin ^a   Harwood, Catherine ^a   Wan, Hong ^a   Odell, Edward W ^e   Hackshaw, Allan ^f   Waseem, Ahmad ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

clinical translation; early cancer biomarkers; early detection; FOXM1 diagnostic biomarkers; molecular diagnostics; personalised medicine; prognostic biomarkers; qPCR; squamous cell carcinoma

Indexed keywords

FOXM1 PROTEIN; MESSENGER RNA; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE; CELL DIFFERENTIATION; CELL RENEWAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; EARLY DIAGNOSIS; EARLY INTERVENTION; EPIGENETICS; FOXM1 GENE; GENE; GENOMIC INSTABILITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LICHEN PLANUS; NORWAY; PRECANCER; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RETROSPECTIVE STUDY; SKIN CARCINOMA; STEM CELL; TREATMENT OUTCOME; UNITED KINGDOM; VULVA CARCINOMA;

ALGORITHMS; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; EARLY DIAGNOSIS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HEAD AND NECK NEOPLASMS; HUMANS; KERATINOCYTES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NORWAY; PRECANCEROUS CONDITIONS; PROGNOSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VULVAR NEOPLASMS;

EID: 84874118632     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27886     Document Type: Article

References (56)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Haddad RI, Shin DM,. Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-54.
3. Baron RC, Melillo S, Rimer BK, et al. Intervention to increase recommendation and delivery of screening for breast, cervical, and colorectal cancers by healthcare providers a systematic review of provider reminders. Am J Prev Med 2010; 38: 110-17.
4. Warnakulasuriya S, Johnson NW, van der Waal I,. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007; 36: 575-80.
5. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
6. Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature 2010; 463: 893-8.
7. Ledford H,. Big science: The cancer genome challenge. Nature 2010; 464: 972-4.
8. Braakhuis BJ, Tabor MP, Kummer JA, et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-30.
9. Braakhuis BJ, Bloemena E, Leemans CR, et al. Molecular analysis of surgical margins in head and neck cancer: more than a marginal issue. Oral Oncol 2010; 46: 485-91.
10. Gemenetzidis E, Costea DE, Parkinson EK, Waseem A, Wan H, Teh MT,. Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res 2010; 70: 9515-26.
11. Teh MT, Gemenetzidis E, Patel D, et al. FOXM1 induces a global methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinoma. PLoS ONE 2012; 7: e34329.
12. Koo CY, Muir KW, Lam EW,. FOXM1: from cancer initiation to progression and treatment. Biochim Biophys Acta 2012; 1819: 28-37.
13. Bose A, Teh M-T, Hutchison IL, et al. Two mechanisms regulate keratin k15 expression in keratinocytes: Role of PKC/AP-1 and FOXM1 mediated signalling. PLoS ONE 2012; 7: e38599.
14. Gemenetzidis E, Bose A, Riaz AM, et al. FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS ONE 2009; 4: e4849.
15. Waseem A, Ali M, Odell EW, et al. Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncol 2010; 46: 536-42.
16. Teh MT, Gemenetzidis E, Chaplin T, et al. Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes. Mol Cancer 2010; 9: 45.
17. Carter SL, Eklund AC, Kohane IS, et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006; 38: 1043-8.
18. Martin KJ, Patrick DR, Bissell MJ, et al. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS ONE 2008; 3: e2994.
19. Chibon F, Lagarde P, Salas S, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 2010; 16: 781-7.
20. Carr JR, Park HJ, Wang Z, et al. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 2010; 70: 5054-63.
21. Kwok JM, Peck B, Monteiro LJ, et al. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 2010; 8: 24-34.
22. Millour J, Constantinidou D, Stavropoulou AV, et al. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene 2010; 29: 2983-95.
23. Millour J, de Olano N, Horimoto Y, et al. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther 2011; 10: 1046-58.
24. Dickson MA, Hahn WC, Ino Y, et al. Human keratinocytes that express hTERT and also bypass a p16(INK4a)- enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 2000; 20: 1436-47.
25. Rheinwald JG, Hahn WC, Ramsey MR, et al. A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 2002; 22: 5157-72.
26. Chang SE, Foster S, Betts D, et al. DOK, a cell line established from human dysplastic oral mucosa, shows a partially transformed non-malignant phenotype. Int J Cancer 1992; 52: 896-902.
27. Gaballah K, Costea DE, Hills A, et al. Tissue engineering of oral dysplasia. J Pathol 2008; 215: 280-9.
28. Rheinwald JG, Beckett MA,. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res 1981; 41: 1657-63.
29. Reiss M, Pitman SW, Sartorelli AC,. Modulation of the terminal differentiation of human squamous carcinoma cells in vitro by all-trans-retinoic acid. J Natl Cancer Inst 1985; 74: 1015-23.
30. Locke M, Heywood M, Fawell S, et al. Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res 2005; 65: 8944-50.
31. Kulkarni PS, Sundqvist K, Betsholtz C, et al. Characterization of human buccal epithelial cells transfected with the simian virus 40 T-antigen gene. Carcinogenesis 1995; 16: 2515-21.
32. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55: 611-22.
33. Zhao S, Fernald RD,. Comprehensive algorithm for quantitative real-time polymerase chain reaction. J Comput Biol 2005; 12: 1047-64.
34. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
35. Bossuyt PM, Reitsma JB,. The STARD initiative. Lancet 2003; 361: 71.
36. Juul N, Szallasi Z, Eklund AC, et al. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 2010; 11: 358-65.
37. Teh MT, Wong ST, Neill GW, et al. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 2002; 62: 4773-80.
38. Myatt SS, Lam EW,. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007; 7: 847-59.
39. Wierstra I, Alves J,. FOXM1, a typical proliferation-associated transcription factor. Biol Chem 2007; 388: 1257-74.
40. Ly DH, Lockhart DJ, Lerner RA, et al. Mitotic misregulation and human aging. Science 2000; 287: 2486-92.
41. Tompkins DH, Besnard V, Lange AW, et al. Sox2 activates cell proliferation and differentiation in the respiratory epithelium. Am J Respir Cell Mol Biol 2011; 45: 101-10.
42. Xie Z, Tan G, Ding M, et al. Foxm1 transcription factor is required for maintenance of pluripotency of P19 embryonal carcinoma cells. Nucleic Acids Res 2010; 38: 8027-38.
43. Lingen MW, Kalmar JR, Karrison T, et al. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol 2008; 44: 10-22.
44. Mehrotra R, Gupta DK,. Exciting new advances in oral cancer diagnosis: avenues to early detection. Head Neck Oncol 2011; 3: 33.
45. Hu S, Arellano M, Boontheung P, et al. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 2008; 14: 6246-52.
46. Ziober BL, Mauk MG, Falls EM, et al. Lab-on-a-chip for oral cancer screening and diagnosis. Head Neck 2008; 30: 111-21.
47. Scully C, Bagan JV, Hopper C, et al. Oral cancer: current and future diagnostic techniques. Am J Dent 2008; 21: 199-209.
48. Woolgar JA, Triantafyllou A,. Pitfalls and procedures in the histopathological diagnosis of oral and oropharyngeal squamous cell carcinoma and a review of the role of pathology in prognosis. Oral Oncol 2009; 45: 361-85.
49. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
50. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
51. Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 2012; 379: 823-32.
52. Chen CH, Chien CY, Huang CC, et al. Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene 2009; 28: 2723-37.
53. Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.
54. Xia JT, Wang H, Liang LJ, et al. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma. Pancreas 2012; 41: 629-35.
55. Liu M, Dai B, Kang SH, et al. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res 2006; 66: 3593-602.
56. Priller M, Poschl J, Abrao L, et al. Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin Cancer Res 2011; 17: 6791-801.